Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

axitinib Articles

Robust growth forecast for renal cell carcinoma market

11 December 2011

Pfizer’s axitinib favored by FDA panel

9 December 2011

US FDA accepts Pfizer NDA for kidney cancer drug axitinib

29 June 2011

Pfizer files for EU approval of axitinib in advanced kidney cancer

2 June 2011

Roundup of upcoming cancer drug trials to be presented at ASCO

20 May 2011

Pfizer commences rolling FDA submission for lung cancer drug crizotinib; denies German VAT evasion

17 January 2011

Bristol-Myers Squibb and Pfizer drop development of apixaban in acute coronary syndrome, but good news for Pfizer with axitinib

22 November 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS